MERIDIA Drug Patent Profile
✉ Email this page to a colleague
When do Meridia patents expire, and when can generic versions of Meridia launch?
Meridia is a drug marketed by Abbott and is included in one NDA.
The generic ingredient in MERIDIA is sibutramine hydrochloride. There are six drug master file entries for this compound. Additional details are available on the sibutramine hydrochloride profile page.
Summary for MERIDIA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 108 |
Clinical Trials: | 13 |
Patent Applications: | 3,827 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MERIDIA at DailyMed |
Recent Clinical Trials for MERIDIA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
New York State Psychiatric Institute | Phase 4 |
AstraZeneca | Phase 4 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for MERIDIA
Paragraph IV (Patent) Challenges for MERIDIA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
MERIDIA | Capsules | sibutramine hydrochloride | 10 mg and 15 mg | 020632 | 1 | 2009-08-14 |
US Patents and Regulatory Information for MERIDIA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-001 | Nov 22, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-002 | Nov 22, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-003 | Nov 22, 1997 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MERIDIA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-003 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-003 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-001 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-002 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-001 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-003 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Abbott | MERIDIA | sibutramine hydrochloride | CAPSULE;ORAL | 020632-002 | Nov 22, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MERIDIA
See the table below for patents covering MERIDIA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Ireland | 820481 | ⤷ Try a Trial | |
Spain | 511152 | ⤷ Try a Trial | |
Netherlands | 300066 | ⤷ Try a Trial | |
Yugoslavia | 75082 | ⤷ Try a Trial | |
Czechoslovakia | 8202457 | ⤷ Try a Trial | |
Egypt | 17770 | A PROCESS FOR THE PREPARATION OF THERAPEUTIC COMPOUND WHICH IS USEFUL IN THE TREATMENT OF DEPRESSION | ⤷ Try a Trial |
United Kingdom | 8629568 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MERIDIA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0397831 | 34/2001 | Austria | ⤷ Try a Trial | PRODUCT NAME: SIBUTRAMINHYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-24052, 1-24053 20010423; FIRST REGISTRATION: LI 54770 19990113 |
0397831 | 300066 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE, IN HET BIJZONDER SIBUTRAMINE HYDROCHLORIDE MONOHYDRAAT; NATL. REGISTRATION NO/DATE: RVG 26281 RVG 26282 20010404; FIRST REGISTRATION: DE 41531.00.00 41531.01.00 41533.01.00 19990114; CH IKS 54770 19990113 |
0230742 | 2001C/040 | Belgium | ⤷ Try a Trial | PRODUCT NAME: MONOHYDRATE DU CHLORHYDRATE DE N,N-DIMETHYL-1-4-CHLOROPHENYL)CYCLOBUTYL-3-METHYLBUTYLAMINE ET COMPOSITIONS PHARMACEUTIQUES LE CONTENANT; NAT. REGISTRTION NO/DATE: 479 IS 52 F 5 20010425; FIRST REGISTRATION: CH 54770 19990113 |
0397831 | 01C0052 | France | ⤷ Try a Trial | PRODUCT NAME: CHLORHYDRATE DE SIBUTRAMINE MONOHYDRATE; REGISTRATION NO/DATE IN FRANCE: NL 23289 DU 20010613; REGISTRATION NO/DATE AT EEC: IKS 54770 DU 19990113 |
0397831 | SPC/GB01/053 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SIBUTRAMINE HYDROCHLORIDE MONOHYDRATE; REGISTERED: DE 41531.00.00 19990114; DE 41531.01.00 19990114; DE 41533.00.00 19990114; DE 41533.01.00 19990114; CH IKS 54770 19990113; UK PL 0169/0129 20010511; UK PL 0169/0130 20010511 |
0397831 | SPC/GB01/053 200210 | United Kingdom | ⤷ Try a Trial | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |